Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach

Area of Science:

• Pharmacology
• Pediatric Drug Development
• Drug Metabolism

Background:

• Children exhibit distinct physiological and biochemical differences from adults, impacting drug metabolism and clearance.
• Glucuronidation is a key metabolic pathway, but its efficiency varies significantly in pediatric populations.
• Accurate prediction of drug clearance in children is crucial for safe and effective dosing.

Purpose of the Study:

• To evaluate the predictive performance of various allometric exponents for total drug clearance in children aged ≤5 years.
• To assess the suitability of adult-derived allometric models for predicting glucuronidated drug clearance in pediatric populations.
• To identify optimal allometric scaling methods for pediatric drug development.

Main Methods:

• Evaluation of four allometric exponents (0.75, 1.0, 1.2, 1.4) applied to body weight.
• Comparison with an allometric model derived from adult data.
• Analysis of ten drugs primarily metabolized via glucuronidation in children ≤5 years.

Main Results:

• A combination of allometric exponents, specifically 1.2 for children ≤3 months and 1.0 for children ≥3 months to 5 years, accurately predicts mean clearance.
• This age-stratified allometric approach demonstrated improved predictive performance compared to a single adult model.
• The findings highlight the importance of age-specific allometric scaling in pediatric pharmacology.

Conclusions:

• The proposed age-dependent allometric model (exponents 1.2 and 1.0) provides a reliable method for predicting drug clearance in young children.
• This approach can aid in estimating initial pediatric doses for clinical trials, facilitating first-in-pediatric studies.
• Optimized dosing strategies based on accurate clearance predictions are essential for advancing pediatric drug development.